Glaxo-Wellcome CEO Sir Richard Sykes has confirmed that the company is moving ahead swiftly with plans to combine AZT, 3TC and abacavir into one tablet. In an interview with Reuters on November 30 Sir Richard Sykes said that Glaxo-Wellcome plans to submit applications to the European and US licensing authorities within the next few weeks.
At the moment, AZT and 3TC can be taken as a single combined tablet twice a day, and abacavir is taken as a single tablet twice a day. The three drug dose will also fit into one tablet, which will be taken twice daily.
This compact regimen will compare favourably with some other triple drug regimens, which can involve taking between 16 and 24 pills daily.